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INTRODUCTION
Respiratory syncytial virus (RSV) is a well-recognized
pathogen in pediatric patients, in whom it causes as many as
90,000 hospitalizations and 4500 deaths annually [1]. Bone
marrow transplant (BMT) recipients are recognized as
being at high risk for RSV infection and for RSV infection
mortality [2,3].
As discussed elsewhere in this supplement (see Englund;
Champlin and Whimbey; Nichols; and Ljungman), upper
respiratory tract infections (URTIs) caused by RSV often
progress to lower respiratory tract infections (LRTIs) in
immunocompromised patients. The mortality rate for these
patients with established RSV LRTI ranges from 30% to
80% [2-5]. Even with the use of therapies available today,
RSV infection in BMT recipients has a mortality rate of
approximately 30% [3,5]. Preventive measures can be impor-
tant in limiting the overall incidence of RSV infection [6],
but even at centers with rigorous infection control programs
in place, some patients develop RSV infections (see Champlin
and Whimbey; and Nichols). It is important, therefore, to
maximize the efﬁcacy of the currently available therapies. 
PREEMPTIVE TREATMENT APPROACH
At the University of Utah Pediatric Bone Marrow
Transplant Unit at Primary Children’s Medical Center in
Salt Lake City, we have taken a preemptive treatment
approach to the management of RSV infection among pedi-
atric BMT recipients. This approach involves identiﬁcation
of patients with asymptomatic RSV shedding followed by
preemptive treatment with aerosolized ribavirin. 
Incidence of Asymptomatic RSV Shedding 
To identify patients at risk of clinical RSV disease, it is
important to know that not all people with RSV infection
are symptomatic. During the 1990 RSV outbreak at the
bone marrow transplant unit at Fred Hutchinson Cancer
Research Center in Seattle, Washington, nasopharyngeal
wash specimens from 435 employees and family members of
patients were screened for RSV using a ﬂuorescent antibody
or shell vial rapid detection test; 347 of these individuals
completed symptom questionnaires [2]. Of the 17 individu-
als who completed the questionnaires and tested positive for
RSV, 3 (18%) were asymptomatic [2].
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Respiratory syncytial virus (RSV) is a cause of serious respiratory infections in pediatric patients. RSV infection may
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developed clinical RSV disease. Two patients had multiple episodes of asymptomatic RSV shedding. One patient
required 2 courses of treatment for clearance of RSV.
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As part of a pilot study on preemptive therapy with
aerosolized ribavirin in pediatric BMT patients at our trans-
plant center [7], we determined the asymptomatic viral shed-
ding rate among our patients and among the staff members
who cared for them. During the RSV season, 25 patients,
who were all ≤20 years of age, were screened for RSV infec-
tion prior to admission and then on a weekly basis as long as
they remained in the transplantation unit. Patients readmit-
ted to the unit for the treatment of complications such as
graft-versus-host disease were also screened. 
Specimens were obtained by nasopharyngeal wash.
Clear specimens were tested with an enzyme-linked
immunosorbent assay (ELISA), and those that tested nega-
tive were retested with a direct ﬂuorescent antibody (DFA)
test. Bloody specimens were tested initially with DFA [7]. 
This testing protocol was used in the 1996 and 1997
RSV seasons: 14 patients were tested in 1996 and 13 were
tested in 1997 (2 patients were tested in both 1996 and
1997, for a total of 25 patients studied). The incidence of
asymptomatic but RSV-positive patients was approximately
7.5% in both years (Table) [7]. Two of these patients were
RSV positive at the time of admission to the unit. 
During the 2 years in which these tests were conducted,
7 of the 25 patients had at least 1 episode of asymptomatic
RSV shedding as conﬁrmed by positive RSV test, for a total
of 11 episodes [7]. Six episodes occurred in the preengraft-
ment phase (including 2 episodes during pretransplantation
conditioning); only 1 episode occurred >100 days after BMT.
Two patients had >1 positive episode; in each case, the posi-
tive episode resolved with treatment. One of these patients
had 3 episodes, including 1 occurring >100 days after trans-
plantation. This patient had tested positive for RSV prior to
transplantation and had been treated with aerosolized rib-
avirin and intravenous RSV immunoglobulin prior to admis-
sion for transplantation. The patient was RSV negative at the
time of transplantation but became RSV positive on day 1
following BMT. This episode and 1 that occurred at day 39
required 2 courses of therapy before RSV tests were nega-
tive. A ﬁnal episode occurred on day 193 [7]. 
Treatment of Asymptomatic RSV Infection
Patients whose test results were positive for RSV on the
preadmission visit had admission delayed, if possible, until
their test results were negative [7]. If the transplant could
not be postponed and the patient was asymptomatic, the
preparation regimen was begun along with a short course of
aerosolized ribavirin (2 g over 2 hours 3 times daily for
5 days), followed by RSV testing 48 and 72 hours after com-
pletion of therapy. If 2 subsequent nasopharyngeal wash
specimens obtained 24 hours apart tested negative for RSV,
the patients were screened on a weekly basis; if their test
results remained positive for RSV, aerosolized ribavirin
treatment was repeated. All patients who became RSV posi-
tive following transplantation were treated and monitored
for RSV in the same manner. Once patients tested negative
for RSV, weekly monitoring was resumed.
During the 2 years of this pilot study, no patient treated
preemptively with aerosolized ribavirin developed a sympto-
matic RSV infection [7]. In all but 1 patient, each episode of
asymptomatic RSV infection cleared with 1 course of therapy. 
Conclusions
The results of this pilot study were encouraging, as all
episodes of asymptomatic RSV cleared following treatment
with aerosolized ribavirin and no episodes of symptomatic
disease emerged. Because this was not a controlled clinical
trial, however, no deﬁnitive conclusions can be drawn about
the efficacy of treatment. It is possible that these patients
would not have developed clinical symptoms of RSV disease
had they remained untreated. To address this issue, a ran-
domized clinical trial has been initiated. 
PEDIATRIC BONE MARROW TRANSPLANT CONSORTIUM
RANDOMIZED TRIAL
To assess the efﬁcacy of treatment of asymptomatic RSV
infection in pediatric BMT recipients, a randomized clinical
trial is being conducted by the Pediatric Bone Marrow
Transplant Consortium. This trial has 3 objectives:
1. to evaluate the signiﬁcance of a positive RSV test in
asymptomatic pediatric BMT recipients; 
2. to evaluate the efﬁcacy of preemptive aerosolized rib-
avirin in preventing emergence of symptomatic disease;
3. to evaluate the safety of aerosolized ribavirin in pre-
emptive therapy.
Patients are eligible for entry if they are <22 years old,
are undergoing an autologous or allogeneic transplant (any
stem cell source), and agree to collection of nasopharyngeal
wash specimens. Informed consent from patients or their
parents or guardians is required. 
Exclusion criteria include evidence of URTI (cough,
sinus congestion, otitis, or conjunctivitis) or LRTI (oxygen
saturation <90%, inﬁltrates on a chest radiograph, or rales
or wheezing on physical examination). 
Patients admitted to the study will be screened for RSV
shedding through testing of nasopharyngeal wash specimens
on a weekly basis. Patients whose specimens test positive for
RSV will be randomized to treatment with aerosolized rib-
avirin (2 g 3 times daily for 5 days) or to observation for signs
and symptoms of clinical disease. Patients in the observation
group who develop evidence of clinical disease will be treated
either with aerosolized ribavirin alone or with aerosolized
ribavirin plus intravenous RSV immunoglobulin or RSV mono-
clonal antibody, according to the investigator’s preference. 
The primary study end point is development of sympto-
matic RSV disease (URTI or LRTI). Secondary end points
include admission to the intensive care unit, intubation,
death from a respiratory cause, length of hospital stay, and
complications of ribavirin therapy.
Incidence of Asymptomatic RSV Infections Among 25 Pediatric BMT
Patients, University of Utah Bone Marrow Transplant Unit, 1996 to 1997* 
1996 1997†
Patients tested 14 13
RSV Tests
Total, no. 38 107
Positive, no. (%) 3 (7.8%) 8 (7.5%)
*Data from [7].




The planned enrollment is 54 patients (27 in each
group). There are clear rules for interim analyses that will
lead to early termination of the study if 1 arm has a superior
outcome. Because of the low incidence of RSV infection,
the study will require 3 to 4 years for completion. Participa-
tion by centers that are not members of the Pediatric Bone
Marrow Consortium is encouraged. 
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